Immodulon, the immuno-oncology company, is pleased to announce that Dr Kevin Bilyard, who served as CEO of Immodulon from 2008 to 2016 and more recently been an advisor to the company’s Board of Directors, has accepted a position on the Immodulon Board.

His career includes senior roles in product development and product strategy at GSK, AstraZeneca and Quadrant Healthcare, prior to its acquisition by Elan. He is the co-founder of a successful international healthcare consultancy business, through which he has worked with many growth stage pharmaceutical companies in Europe and the US.